Omthera Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Princeton NJ United States (2008)
Status: Acquired by AstraZeneca (2013)

Organization Overview

First Clinical Trial
2011
NCT01242527
First Marketed Drug
2014
omega-3-carboxylic acids (epanova)
First NDA Approval
2014
omega-3-carboxylic acids (epanova)
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Omthera Pharmaceuticals/AstraZeneca | Omthera Pharmaceuticals, Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 3)

Hypertriglyceridemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7